FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

MRI-based prostate cancer screening of the general population does not increase detection of clinically significant prostate cancer, but it does improve the benefit-vs-harm profile of PSA testing ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

MRI reports and biopsy pathology reports were extracted from a cohort of 1,360,866 patients with PCa in the VA Cancer Registry System or the VA Corporate Data Warehouse, with 155,570 patients having ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...